fda warning letters glp-1 compounders september 2025 news compounding The Food and Drug Administration (FDA) on Tuesday FDA takes aim at telehealth

Description

AltRx GLP-1 is a telehealth-based weight loss program that provides access to prescription GLP-1 medications without requiring in-person clinic visits

Yeah, I didnt even think of this because then Yeah, it is interesting

The FDA has active counterfeit Ozempic warnings

22 Outcomes Our primary outcome was the duration of expected protection from generic competition

Higher values are associated with: Impaired liver metabolism and fatty liver disease Poor glucose control and worsening insulin resistance Increased cardiovascular and stroke risk Chronic low-grade inflammation Even normal weight individuals may show elevated visceral fat on InBody analysis, revealing a hidden metabolic risk that BMI cannot detect